Tel: 01892 526726     Email:     Twitter

Broad and learned
clinical background

Gut Reactions #1 – a new biosimilar candidate for infliximab

Remicade (infliximab) was approved in 1998 for the treatment of Crohn’s disease and ulcerative colitis. Infliximab is a biologic drug, as opposed to a chemical drug. Biologic drugs are genetically engineered proteins derived from human genes, and are manufactured in ...

Read more